Monoclonal B-Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect [0.03%]
单克隆B细胞淋巴细胞增多症：血液学家不应忽视的沉默性克隆
Andrea Serafin,Emanuela Sant&#x;Antonio,Fabrizio Mavilia et al.
Andrea Serafin et al.
Monoclonal B-cell lymphocytosis (MBL) is a hematologic condition defined by the presence of a small clonal B-cell population in the peripheral blood, without clinical or laboratory evidence of lymphoproliferative disorders. It is classified...
T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma [0.03%]
大B细胞淋巴瘤和滤泡性淋巴瘤中的T细胞重定向策略
Gloria Iacoboni
Gloria Iacoboni
The advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory large B-cell lymphoma (LBCL). After achieving regulatory approval in third line (3L+), randomized trials confirme...
A Comparative Study of Bone Marrow and Central Nervous System Microenvironment Models to Improve In Vitro Studies of Acute Lymphoblastic Leukemia [0.03%]
改进急性淋巴细胞白血病体外研究的骨髓和中枢神经系统微环境模型的比较研究
Katrine Juhlin Kiørboe,Joana Serwaa Akoto,Morten Juhl Nørgaard et al.
Katrine Juhlin Kiørboe et al.
The bone marrow (BM) niche plays a critical role in the development of acute lymphoblastic leukemia (ALL), while the central nervous system (CNS) is a common site of dissemination. Existing in vitro models of childhood ALL lack complexity a...
Comparative Study
Hematological oncology. 2025 Jul;43(4):e70108. DOI:10.1002/hon.70108 2025
A Meta-Analysis on Gilteritinib Using Real-World and Randomized Trial Data in Patients With FLT3-Mutated Refractory/Relapsed Acute Myeloid Leukemia [0.03%]
基于真实世界和随机试验数据的gilteritinib治疗FLT3突变型难治性/复发急性髓系白血病患者的meta分析
Matteo Molica,Giannarelli Diana,Salvatore Perrone
Matteo Molica
Antonella Bruzzese,Ernesto Vigna,Enrica Antonia Martino et al.
Antonella Bruzzese et al.
TP53-mutated acute myeloid leukemia (AML) remains one of the most treatment-resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, ap...
Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off Approach [0.03%]
连续变量与时间到事件结果关联的研究：超越分组法
Tesla Murairi Mirimo,Cédric Portugues,Laurent Remontet et al.
Tesla Murairi Mirimo et al.
When describing relationships between variables and an outcome, dichotomization of continuous variables remains a widely used approach in medical research despite many drawbacks: the loss of information which reduces the statistical power t...
Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms [0.03%]
基于先天免疫的聚类揭示了我的elodysplastic肿瘤根据疾病严重程度的不同调节功能障碍
Pedro Robson Costa Passos,Andréa Alcântara Vieira,Renata Pinheiro Martins de Melo et al.
Pedro Robson Costa Passos et al.
Myelodysplastic neoplasms (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia (AML). Despite growing recognition of the role of innate immunity in MD...
MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B-Cell Lymphoma [0.03%]
MerTK在弥漫大B细胞淋巴瘤的异位表达及其生物学功能影响
Yan Li,Cunzhen Shi,Jiazhuo Wu et al.
Yan Li et al.
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients do not receive standard rescue treatment; therefore, the exploration of new therapeutic targets for the treatment of DLBCL is urgently needed. Immunohistochemistry and weste...
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort Study [0.03%]
老年体弱弥漫性大B细胞淋巴瘤患者R-miniCOMP与R-miniCHOP的疗效比较——一项“意大利淋巴瘤研究基金会”队列研究报告的新见解
Alberto Bavieri,Sara Veronica Usai,Michele Merli et al.
Alberto Bavieri et al.
The R-miniCHOP regimen is the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL) in older unfit or frail patients. Recent research suggests that replacing doxorubicin with non-PEGylated liposomal doxorubicin (NPLD) is s...
Comparative Study
Hematological oncology. 2025 May;43(3):e70099. DOI:10.1002/hon.70099 2025
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND [0.03%]
阿西替雷利姆治疗亚洲复发或难治性弥漫大B细胞淋巴瘤患者的疗效与历史对照：ZUMA-1对比REAL-TREND的匹配调整间接比较分析
Frederick L Locke,Graeme Ball,Markqayne D Ray et al.
Frederick L Locke et al.
To better understand the comparative effectiveness of axicabtagene ciloleucel (axi-cel) to historical standard of care (SoC) for the treatment of refractory diffused large B-cell lymphoma (DLBCL) among patients of Asian descent, we conducte...
Comparative Study
Hematological oncology. 2025 May;43(3):e70100. DOI:10.1002/hon.70100 2025